MarketPulse

breast cancer

27 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Boundless Bio Extends Cash Runway to Mid-2028 Amid BBI-940 Clinical Expansion

Boundless Bio reported $107.6M cash, narrowed 2025 net losses to $58.2M, and is advancing lead breast cancer candidate BBI-940 through Phase 2 trials.
BOLDbreast cancercash runway
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Accelerates FLAMINGO-01 Trial With 33% Patient Screening Surge

Greenwich LifeSciences boosts FLAMINGO-01 screening by 33% to 800 patients yearly, with non-HLA-A*02 arm fully enrolled and showing 80% recurrence reduction.
GLSIbreast cancerGLSI-100
GlobeNewswire Inc.GlobeNewswire Inc.··Alx Oncology Holdings Inc.

ALX Oncology Narrows Losses, Secures Funding as Clinical Pipeline Advances

ALX Oncology reduced losses and secured $150M in funding, extending cash runway to mid-2028. The company advances its clinical pipeline with CD47 biomarker validation for its cancer therapies.
ALXOclinical trialsevorpacept
BenzingaBenzinga··Vandana Singh

Bristol Myers' Experimental Breast Cancer Treatment Demonstrates Survival Gains in Advanced Patients

Bristol Myers Squibb's experimental breast cancer drug showed survival improvements in advanced patients, though stock declined slightly following the announcement.
BMYCELGrbreast cancerPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Presents FLAMINGO-01 Trial Data at AACR 2026 Conference

Greenwich LifeSciences presents FLAMINGO-01 Phase III trial data at AACR 2026, showing 80% recurrence reduction. Non-HLA-A*02 arm fully enrolled with 250 patients.
GLSIbreast cancerGLSI-100
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Celcuity as Stock Ascends 700% YoY

Perceptive Advisors doubled its Celcuity stake to 5.62% of AUM, making it the fund's second-largest holding. Stock surged 700% YoY ahead of expected FDA approval for lead drug Gedatolisib.
CELCFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relay Therapeutics to Report 2025 Results Ahead of Phase 3 Pipeline Milestones

Relay Therapeutics reports 2025 results February 26, highlighting progress on lead drug zovegalisib advancing through Phase 3 trials with FDA Breakthrough Therapy Designation.
RLAYPhase 3 clinical trialFDA Breakthrough Therapy Designation